Disease relevance of Rimiterol

• Rimiterol and the prevention of exercise-induced asthma [1].
• 3 Rimiterol 0.5% and salbutamol 0.25% produced similar peak mean improvements in FEV and also induced the same degree of tachycardia, but the duration of these effects were significantly shorter in the case of rimiterol [2].
• Thirty-six patients with a combination of reversible and persistent airway obstruction were treated with ipratropium bromide, salbutamol and a combination of both in high dose by nebulizer after a control period of rimiterol [3].

High impact information on Rimiterol

• After inhalation of rimiterol, there were no significant changes in FEV1 [1].
• Ten athletes with asthma (15 to 30 years of age) undertook 8 minutes of submaximal exercise (80% of anaerobic threshold) on the treadmill ergometer, once after inhaling rimiterol and once after inhaling a placebo [1].
• 1 The potencies relative to isoprenaline of isoetharine, tertiary butyl noradrenaline, salbutamol, orciprenaline, Me 506, rimiterol, fenoterol, carbuterol and terbutaline on isolated preparations of guinea-pig trachea and blood vessels (perfused hind limb) were determined [4].
• There were no significant differences between the two forms with regard to symptom score, extra use of rimiterol aerosol, heart rate or blood pressure [5].
• 2 A cumulative dose of rimiterol (1050 microgram) given in six separate injections over 90 min resulted in a mean increase in peak expiratory flow rate (PEFR) of 50.6% and FEV1 of 53.7% [6].

Biological context of Rimiterol

• However, in the controls the second dose of rimiterol, given 2 h after the first, was responsible for only a small increase in heart rate which was not significantly different than that after saline in the other three treatment groups [2].
• 3 Rimiterol (98%), salbutamol (96%) and isoprenaline (69%) protected against histamine-induced bronchoconstriction [7].
• 3. Isoprenaline in contrast with rimiterol produced direct coronary vasodilation, i.e. coronary vasodilation in excess of that required to meet increases in myocardial oxygen demands [8].

Anatomical context of Rimiterol

• Some evidence for the extraneuronal uptake of rimiterol and its metabolism by catechol-O-methyltransferase in guinea-pig trachealis smooth muscle cells [9].

Associations of Rimiterol with other chemical compounds

• Further studies of rimiterol and salbutamol administered by intermittent positive-pressure ventilation, and an important observation on the technique of using the Bennett ventilator [2].
• In this study, regular inhalation treatment of rimiterol seemed to be as effective as terbutaline in long-term bronchodilator therapy [10].

Gene context of Rimiterol

• Comparative potencies and beta2-adrenoreceptor selectivities of rimiterol and salbutamol aerosols [11].
• However, despite the increase in the magnitude of LAR on the rimiterol day, the reduction in postchallenge PC20 did not differ significantly from that occurring on the control day.(ABSTRACT TRUNCATED AT 250 WORDS)[12]
• The bronchodilating efficacy and the degree of beta2-selectivity of rimiterol, salbutamol and isoprenaline were determined in seven asthmatic patients [13].

Analytical, diagnostic and therapeutic context of Rimiterol

• Two puffs (400 micrograms) of rimiterol or placebo were administered in a double-blind crossover manner 2 minutes before each exercise test [1].
• Effect of intravenous injection of rimiterol in asthma [6].

References